Skip to main content

Table 3 Overall response of QL1706 in different tumor types in patients who received QL1706 at 5 mg/kg every 3 weeks (RP2D)

From: First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

 

All patient (n = 468)

NSCLC (n = 121)

NPC (n = 110)

CC (n = 55)

CRC (n = 27)

SCLC (n = 26)

HCC (n = 25)

Biliary tract carcinoma(n = 21)

Breast cancer (n = 19)

Kidney cancer (n = 18)

Ovarian cancer (n = 8)

Melanoma (n = 6)

Neuroendocrine tumor (n = 6)

Esophageal cancer (n = 5)

Gastric cancer (n = 3)

Others (n = 18)

CR

1 (0.2)

0

0

1 (1.8)

0

0

0

0

0

0

0

0

0

0

0

0

PR

78 (16.7)

17 (14.0)

27 (24.5)

14 (25.5)

2 (7.4)

6 (23.1)

0

0

1 (5.3)

5 (27.8)

1 (12.5)

2 (33.3)

2 (33.3)

0

0

1 (5.6)

SD

129 (27.6)

37 (30.6)

27 (24.5)

14 (25.5)

5 (18.5)

3 (11.5)

10 (40.0)

9 (42.9)

4 (21.1)

8 (44.4)

3 (37.5)

1 (16.7)

2 (33.3)

2 (40.0)

0

4 (22.2)

PD

213 (45.5)

52 (43.0)

52 (47.3)

18 (32.7)

18 (66.7)

11 (42.3)

15 (60.0)

12 (57.1)

12 (63.2)

4 (22.2)

3 (37.5)

1 (16.7)

1 (16.7)

2 (40.0)

3 (100)

9 (50.0)

NE

2 (0.4)

0

0

1 (1.8)

1 (3.7)

0

0

0

0

0

0

0

0

0

0

0

ND

45 (9.6)

15 (12.4)

4 (3.6)

7 (12.7)

1 (3.7)

6 (23.1)

0

0

2 (10.5)

1 (5.6)

1 (12.5)

2 (33.3)

1 (16.7)

1 (20.0)

0

4 (22.2)

Confirmed ORR, n (%, 95% CI)

79 (16.9, 13.6–20.6)

17 (14.0, 8.4–21.5)

27 (24.5, 16.8–33.7)

15 (27.3, 16.1–41.0)

2 (7.4, 0.9–24.3)

6 (23.1, 9.0–43.6)

0

0

1 (5.3, 0.1–26.1)

5 (27.8, 9.7–53.5)

1 (12.5, 0.3–52.7

2 (33.3, 4.3–77.7)

2 (33.3, 4.3–77.7)

0

0

1 (5.6, 0.1–27.3)

DCR, n (%, 95% CI)

208 (44.4, 39.9–49.1)

54 (44.6, 35.6–53.9)

54 (49.1, 39.4–58.8)

29 (52.7, 38.8–66.3)

7 (25.9, 11.1–46.3)

9 (34.6, 17.2–55.7)

10 (40.0, 21.1–61.3)

9 (42.9, 21.9–66.0)

5 (26.3, 9.1–51.2)

13 (72.2, 46.5–90.3)

4 (50, 15.7–84.3)

3 (50.0, 11.8–88.2)

4 (66.7, 22.3–95.7)

2 (40.0, 5.3–85.3)

0

5 (27.8, 9.7–53.4)

Number of DoR events (%)

20 (25.3)

5 (29.4)

9 (33.3)

2 (13.3)

1 (50.0)

1 (16.7)

/

/

1 (100)

0

/

1 (50.0)

0

/

/

0

DoR, m (95% CI)

11.7 (8.3, –)

 − (4.7, –)

11.7 (7.7, –)

 − (–, –)

 − (2.9, –)

 − (4.2, –)

/

/

/

 − (–, –)

/

 − (5.4, –)

 − (–, –)

/

/

/

  1. CRC Colorectal cancer, SCLC Small cell lung cancer, HCC Hepatocellular carcinoma, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, NE Not evaluated, ND Not determined, ORR Objective response rate, DCR Disease control rate, CI Confidence interval
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us